New Small Molecule PT-13 Shows Promise in Disaggregating Tau Pathology in Alzheimer's Disease Models
Researchers have developed a coumarin-based small molecule called PT-13 that disaggregates the tau protein tangles associated with Alzheimer's disease and related conditions. Unlike existing approaches, PT-13 is brain-penetrant, reduces both fibrillar and oligomeric tau burden, and does not produce toxic intermediate byproducts during the disaggregation process. The findings, published as a preprint on bioRxiv, suggest that directly targeting existing tau aggregates — rather than preventing their formation — may be a viable therapeutic strategy for tauopathies.
A team of researchers has identified PT-13, a lead compound from a coumarin-based small-molecule series, that can disaggregate pathological tau fibrils and oligomers through a mechanism described as stacking-driven co-assembly. The compound was shown to inhibit tau seeding using brain-derived material from Alzheimer's disease patients and reduced aggregate burden across multiple tau species. A key mechanistic finding is that the disaggregation process does not generate soluble oligomeric intermediates, which have been a concern in the field as potential sources of additional toxicity. PT-13 demonstrated brain penetrance and tolerability in animal studies, and in a tauopathy mouse model it reduced tau pathology while preserving behavioral function, proteasome capacity, and synaptic integrity. Currently, no approved therapy is capable of eliminating existing tau neurofibrillary tangles, making this class of aggregate-directed compounds a potentially significant advance. The authors argue their work provides a molecular framework for designing future therapeutics targeting tau aggregates in neurodegeneration. The study is currently a preprint and has not yet undergone formal peer review.
What's missing
As a preprint, this study has not yet undergone peer review. Key limitations and open questions include whether PT-13's efficacy and safety will translate from mouse models to humans, what the compound's pharmacokinetic profile and therapeutic window look like in primates, and whether long-term exposure produces any adverse effects. The specific mouse tauopathy model used and how closely it recapitulates human Alzheimer's disease pathology are also important caveats not detailed in the abstract.
What different sources said
- bioRxivCenter
Tau Disaggregation by a CNS-Permeable Small Molecule Reduces Fibril and Oligomer Burden and Preserves Proteostasis and Behavior
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.